HomeNewscoronavirusIncrease Covishield dose gap to 6-8 weeks, Centre tells states

Increase Covishield dose gap to 6-8 weeks, Centre tells states

This time interval between two doses has been revised only for Covishield and not Covaxin.

March 23, 2021 / 00:05 IST
Story continues below Advertisement

The interval between two doses of Covishield vaccine should be increased to six-eight weeks, the Centre has said in a letter to state governments on March 22. At present, the two-dose vaccine is being administered four to six weeks apart.

Based on the feedback received from the National Technical Advisory Group on Immunization (NTAGI) and subsequently by the National Expert Group on Vaccine Administration for COVID-19(NEGVAC), it was decided to recommend an increase in the interval period between the two Covishield doses, the government said in a statement.

Story continues below Advertisement

"Keeping the existing scientific evidence in view, it appears that protection is enhanced if the second dose of Covishield is administered between six to eight weeks, but not later than stipulated period of eight weeks," the Centre said.

The decision has been conveyed to states and union territories through a letter written by Union Health Secretary Rajesh Bhushan.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show